Back to search
FDAFDA · Food and drugs·Recall number D-0548-2024

Prednisolone-Moxifloxacin-Bromfenac Sterile Ophthalmic Suspension, 1%, 0.5%, 0.075%, 5mL, Quantity: 20mL, Rx Only, Compounded by: Imprimis NJOF, LLC. 1705 Route 46 West, Unit 6B Ledgewood, NJ NDC 71384-310-05

Published June 19, 2024 · Recall initiated: May 14, 2024

Summary

FDA records drug Class II recall D-0548-2024, published June 19, 2024 and initiated May 14, 2024. Recalling firm: Imprimis NJOF, LLC; Status: Ongoing; Reported quantity: 4,280 boxes; Lot: Lot: 23NOV018 Exp. 6/17/24. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.

Status when published: Ongoing — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

Lack of Assurance of Sterility

What to do

Voluntary: Firm initiated

Get an email when a new FDA recall like this is published

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Manufacturer
Imprimis NJOF, LLC
Distributor
US Nationwide
Lot
Lot: 23NOV018 Exp. 6/17/24
Risk classification
Class II
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was Prednisolone-Moxifloxacin-Bromfenac Sterile Ophthalmic Suspension, 1%, 0.5%, 0.075%, 5mL, Quantity: 20mL, Rx Only, Compounded by: Imprimis NJOF, LLC. 1705 Route 46 West, Unit 6B Ledgewood, NJ NDC 71384-310-05 recalled?

Yes. FDA published recall D-0548-2024 on June 19, 2024. Reported hazard: Lack of Assurance of Sterility

What should I do if I have this product?

Voluntary: Firm initiated